Clinical Research Directory
Browse clinical research sites, groups, and studies.
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
Sponsor: Portal Therapeutics, Inc.
Summary
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
Official title: A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
108
Start Date
2024-04-08
Completion Date
2025-08-29
Last Updated
2025-04-04
Healthy Volunteers
Yes
Conditions
Interventions
PORT-77
Healthy adult participants will receive a single oral dose of PORT 77.
Placebo
Healthy adult participants will receive matching placebo on Day 1.
Locations (1)
Celerion
Tempe, Arizona, United States